FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912760105> ?p ?o ?g. }

• W2912760105 endingPage "1191" @default.
• W2912760105 startingPage "1177" @default.
• W2912760105 abstract "Treatment for melanoma is a challenging clinical problem, and some new strategies are worth exploring.The objective of this study was to investigate the in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles (HANPs) and discuss the involved material factors.Five types of HANPs, ie, HA-A, HA-B, HA-C, HA-D, and HA-E, were prepared by wet chemical method combining with polymer template and appropriate post-treatments. The in vitro effects of the as-prepared five HANPs on inhibiting the viability of A375 melanoma cells and inducing the apoptosis of the cells were evaluated by Cell Counting Kit-8 analysis, cell nucleus morphology observation, flow cytometer, and PCR analysis. The in vivo anti-melanoma effects of HANPs were studied in the tumor model of nude mice.The five HANPs had different physicochemical properties, including morphology, size, specific surface area (SSA), crystallinity, and so on. By the in vitro cell study, it was found that the material factors played important roles in the anti-melanoma effect of HANPs. Among the as-prepared five HANPs, HA-A with granular shape, smaller size, higher SSA, and lower crystallinity exhibited best effect on inhibiting the viability of A375 cells. At the concentration of 200 μg/mL, HA-A resulted in the lowest cell viability (34.90%) at day 3. All the HANPs could induce the apoptosis of A375 cells, and the relatively higher apoptosis rates of the cells were found in HA-A (20.10%) and HA-B (19.41%) at day 3. However, all the HANPs showed no inhibitory effect on the viability of the normal human epidermal fibroblasts. The preliminary in vivo evaluation showed that both HA-A and HA-C could delay the formation and growth speed of melanoma tissue significantly. Likely, HA-A exhibited better effect on inhibiting the growth of melanoma tissue than HA-C. The inhibition rate of HA-A for tumor tissue growth reached 49.1% at day 23.The current study confirmed the anti-melanoma effect of HANPs and provided a new idea for the clinical treatment of melanoma." @default.
• W2912760105 created "2019-02-21" @default.
• W2912760105 creator A5011299026 @default.
• W2912760105 creator A5045069173 @default.
• W2912760105 creator A5050407938 @default.
• W2912760105 creator A5053275663 @default.
• W2912760105 creator A5061300084 @default.
• W2912760105 creator A5074967076 @default.
• W2912760105 creator A5081948792 @default.
• W2912760105 creator A5087611823 @default.
• W2912760105 creator A5088873947 @default.
• W2912760105 creator A5091791565 @default.
• W2912760105 date "2019-02-01" @default.
• W2912760105 modified "2023-10-16" @default.
• W2912760105 title "<p>The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: influences of material factors</p>" @default.
• W2912760105 cites W1656274176 @default.
• W2912760105 cites W1745634660 @default.
• W2912760105 cites W1970179905 @default.
• W2912760105 cites W1987334928 @default.
• W2912760105 cites W1992431968 @default.
• W2912760105 cites W1996899045 @default.
• W2912760105 cites W2003491428 @default.
• W2912760105 cites W2011194583 @default.
• W2912760105 cites W2018789178 @default.
• W2912760105 cites W2019083595 @default.
• W2912760105 cites W2023440396 @default.
• W2912760105 cites W2025087492 @default.
• W2912760105 cites W2025519344 @default.
• W2912760105 cites W2025973123 @default.
• W2912760105 cites W2035880736 @default.
• W2912760105 cites W2036145275 @default.
• W2912760105 cites W2036419055 @default.
• W2912760105 cites W2040804698 @default.
• W2912760105 cites W2042141743 @default.
• W2912760105 cites W2053004997 @default.
• W2912760105 cites W2057193930 @default.
• W2912760105 cites W2057287977 @default.
• W2912760105 cites W2066496284 @default.
• W2912760105 cites W2070061125 @default.
• W2912760105 cites W2082821194 @default.
• W2912760105 cites W2089040209 @default.
• W2912760105 cites W2103901963 @default.
• W2912760105 cites W2110252008 @default.
• W2912760105 cites W2119822961 @default.
• W2912760105 cites W2123952240 @default.
• W2912760105 cites W2128917727 @default.
• W2912760105 cites W2129637849 @default.
• W2912760105 cites W2135480474 @default.
• W2912760105 cites W2139039144 @default.
• W2912760105 cites W2141862632 @default.
• W2912760105 cites W2151501496 @default.
• W2912760105 cites W2155127143 @default.
• W2912760105 cites W2166664821 @default.
• W2912760105 cites W2171038175 @default.
• W2912760105 cites W221329581 @default.
• W2912760105 cites W2269708716 @default.
• W2912760105 cites W2283809535 @default.
• W2912760105 cites W2323960045 @default.
• W2912760105 cites W2324775231 @default.
• W2912760105 cites W2346529982 @default.
• W2912760105 cites W2413587111 @default.
• W2912760105 cites W2509916100 @default.
• W2912760105 cites W2539792805 @default.
• W2912760105 cites W2753782603 @default.
• W2912760105 cites W2766444361 @default.
• W2912760105 cites W2789641767 @default.
• W2912760105 cites W2884787683 @default.
• W2912760105 cites W4255760236 @default.
• W2912760105 doi "https://doi.org/10.2147/ijn.s184792" @default.
• W2912760105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6391145" @default.
• W2912760105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30863053" @default.
• W2912760105 hasPublicationYear "2019" @default.
• W2912760105 type Work @default.
• W2912760105 sameAs 2912760105 @default.
• W2912760105 citedByCount "26" @default.
• W2912760105 countsByYear W29127601052019 @default.
• W2912760105 countsByYear W29127601052020 @default.
• W2912760105 countsByYear W29127601052021 @default.
• W2912760105 countsByYear W29127601052022 @default.
• W2912760105 countsByYear W29127601052023 @default.
• W2912760105 crossrefType "journal-article" @default.
• W2912760105 hasAuthorship W2912760105A5011299026 @default.
• W2912760105 hasAuthorship W2912760105A5045069173 @default.
• W2912760105 hasAuthorship W2912760105A5050407938 @default.
• W2912760105 hasAuthorship W2912760105A5053275663 @default.
• W2912760105 hasAuthorship W2912760105A5061300084 @default.
• W2912760105 hasAuthorship W2912760105A5074967076 @default.
• W2912760105 hasAuthorship W2912760105A5081948792 @default.
• W2912760105 hasAuthorship W2912760105A5087611823 @default.
• W2912760105 hasAuthorship W2912760105A5088873947 @default.
• W2912760105 hasAuthorship W2912760105A5091791565 @default.
• W2912760105 hasBestOaLocation W29127601051 @default.
• W2912760105 hasConcept C12554922 @default.
• W2912760105 hasConcept C1491633281 @default.
• W2912760105 hasConcept C150903083 @default.
• W2912760105 hasConcept C153911025 @default.
• W2912760105 hasConcept C155672457 @default.
• W2912760105 hasConcept C159985019 @default.

• next